APIRx-1603 is under clinical development by Incannex Healthcare and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.
GlobalData’s report assesses how APIRx-1603’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APIRx-1603 overview
APIRx-1603 is under development for the treatment of atopic dermatitis. The therapeutic candidate is a cannabinoid. It is administered through topical route. The drug candidate acts by targeting cannabinoid receptor 1 and cannabinoid receptor 2.
It was also under development for the treatment of glaucoma for ophthalmic route
Incannex Healthcare overview
Incannex Healthcare, is a pharmaceutical company. The company offers the development and manufacturing of cannabinoid medicine and therapeutic products. Its product portfolio includes releafia, nutralesic, inflammex, and cannagesia. Incannex Healthcare products are used in the treatment of obstructive sleep apnea, traumatic brain injury, sepsis-associated acute respiratory distress syndrome, and temporomandibular joint dysfunction. It also provides clinical trials and research and development services. It operates in Australia and New Zealand. Incannex Healthcare is headquartered in Melbourne, Victoria, Australia.
